Summit Therapeutics has named its research and development adviser Dr David Roblin as new Chief Operating Officer (COO) and President of Research Development.
Dr Roblin will start with the new role on an interim basis in April 2017, and it will become full-time in June 2017.
Dr Roblin had worked at Pfizer and Bayer, where he had senior positions. Most recently, Dr Roblin worked as a COO and Director of Scientific Translation at the Francis Crick Institute, a London-based biomedical institute.
Glyn Edwards, Chief Executive Officer of Summit said: “David has had a distinguished career in the biopharmaceutical industry with over 25 years of experience, and we are delighted he is committing himself to Summit as COO and President of R&D. David will be instrumental to Summit as we continue to advance our two important medicines in DMD and CDI through late-stage clinical trials.”
Dr David Roblin said: ““Summit has two strong scientific programmes with the potential to significantly advance the current standard of care in their respective disease areas. In CDI, the positive results from Summit’s Phase 2 proof of concept trial highlight ridinilazole’s impressive translational medicine story, and in DMD, we are nearing the first data from our Phase 2 trial of ezutromid evaluating the mechanism for utrophin modulation. As we continue to advance both programmes in the clinic, I look forward to working with the team with the goal of delivering success for patients and their families, and our shareholders.”